Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in residual esophageal cancer
NCT02639065Phase 2Completed
- Start
- Apr 2016
- Primary completion
- Dec 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in esophageal adenocarcinoma (EAC). Started Apr 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT02639065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639065.